Previous 10 | Next 10 |
Summary According to a Wall Street Journal report, China and the US are close to solving the accounting rules crisis that threatens to de-list 261 China companies from US exchanges. Lee's Pharm of Hong Kong entered a $78.9 million deal with Windtree Therapeutics for global rights ...
Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global, biotechnology company developing, manufacturing and commercializing novel therapies to treat life-threatening diseases, today in conjunction with an announcement to be issued by Legend Biotech’s majority shareh...
CSPC Pharma out-licensed global rights (ex-China) for its antibody drug conjugate targeting Claudin18.2 to Elevation Oncology of New York City. Chengdu’s Kelun-Biotech out-licensed global rights to an ADC candidate aimed at solid tumors to MSD (Merck) in a deal worth up to $936...
Shares of Legend Biotech (NASDAQ: LEGN) rose 11.8% on Wednesday. The company, which specializes in immunotherapy cell therapies, is up a little more than 3% for the year. There are two reasons for the rise in the stock, both related to the Chinese biotech company's announcement ...
Legend Biotech ( NASDAQ: LEGN ) priced an underwritten public offering of 8.14M ADSs, each representing two ordinary shares, at a public offering price of $43/ADS for total gross proceeds of ~$350M. Underwriters granted 30-day option to purchase up to an additional 1....
Gainers: Sunshine Biopharma ( SBFM ) +26% . InflaRx IFRX +14% . Talaris Therapeutics ( TALS ) +8% . Nutriband ( NTRB ) +7% . Biodesix ( BDSX ) +5% . Losers: Revelation Biosciences REVB -52% . Virax Biolabs VR...
Legend Biotech ( NASDAQ: LEGN ) shares dropped ~6% in extended trading on Monday after the biotechnology company proposed a public offering of $250M of American Depositary Shares (ADSs). Underwriters will be granted a 30-day option to purchase up to an additional $37.5...
For further details see: Arcellx named new buy at Canaccord Genuity on multiple myeloma candidate
Clinical-stage biotech biopharmaceutical company Legend Biotech Corporation ( NASDAQ: LEGN ) announced on Thursday that the company ended its Phase 1 Clinical Trial for CAR-T candidate LB1901 involving adults with relapsed or refractory T-cell lymphoma. Legend ( LEGN )...
The eleven sectors of the S&P 500 were 16.4% lower for Q2 2022, with SPDR S&P 500 Trust ETF closed more than 16% lower . The top five gainers in the health care sector (stocks with a market cap of over $2B) were: Turning Point Therapeutics ( TPTX ) +179.1...
News, Short Squeeze, Breakout and More Instantly...
Legend Biotech Corporation Company Name:
LEGN Stock Symbol:
NASDAQ Market:
Legend Biotech Corporation Website:
SOMERSET, N.J., July 10, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, will host a conference call for investors at 8:00 am ET on Friday, August 9, 2024, to review second-quarter 2024 results. During the webcast and confe...
SOMERSET, N.J., July 02, 2024 (GLOBE NEWSWIRE) -- Legend Biotech Corporation (NASDAQ: LEGN) (Legend Biotech), a global leader in cell therapy, announced today positive overall survival results from CARTITUDE-4, an ongoing, global randomized, open-label Phase 3 study evaluating the efficacy and sa...
2024-06-20 17:01:11 ET USA News Group News Commentary Issued on behalf of Oncolytics Biotech Inc. VANCOUVER – June 20,2024 – USA News Group News Commentary – The potential threat of cancer looms for everyone, but now new studies are revealing an increased number o...